Form 4: Theravance Biopharma Executive Aine Miller Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Aine Miller, SVP at Theravance Biopharma, disposed of 11,295 ordinary shares to cover tax obligations related to vesting restricted stock units.
Summary
- A Form 4 filing reveals that Aine Miller, SVP at Theravance Biopharma, disposed of 11,295 ordinary shares on February 20, 2025.
- The shares were disposed of to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was conducted with the issuer and did not involve an open market transaction.
- Following the transaction, Miller directly owns 139,261 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock transaction for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock. This filing indicates a routine transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of share disposal transaction. |
| 02/24/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Theravance Biopharma, TBPH, Aine Miller, Share Disposal, Tax Obligations, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.